Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 3;19(10):e0309796.
doi: 10.1371/journal.pone.0309796. eCollection 2024.

Time to major adverse drug reactions and its predictors among children on antiretroviral treatment at northwest Amhara selected public hospitals northwest; Ethiopia, 2023

Bantegizie Senay Tsega  1 , Abebe Habtamu  2 , Moges Wubie  2 , Animut Takele Telayneh  2 , Bekalu Endalew  2 , Samuel Derbie Habtegiorgis  2 , Molla Yigzaw Birhanu  2 , Worku Misganaw Kebede  3 , Keralem Anteneh Bishaw  4
Affiliations

Time to major adverse drug reactions and its predictors among children on antiretroviral treatment at northwest Amhara selected public hospitals northwest; Ethiopia, 2023

Bantegizie Senay Tsega et al. PLoS One. .

Abstract

Background: Adverse drug reaction is one of the emerging challenges in antiretroviral treatment. Determining the incidence rate and predictors among children on antiretroviral treatment (ART) is essential to improve treatment outcomes and minimize harm. And also, evidence regarding the time to major adverse drug reactions and its predictors among children on antiretroviral treatment is limited in Ethiopia.

Objective: This study aimed to assess the time to major adverse drug reaction and its predictors among children on antiretroviral treatment at selected public hospitals in Northwest Amhara, Ethiopia, 2023.

Method: A retrospective cohort study was conducted among 380 children on antiretroviral treatment who enrolled from June 27, 2017, to May 31, 2022. Data was collected using a structured data extraction checklist. Data were entered into Epidata 4.6 and analyzed using STATA 14. The incidence rate of major adverse drug reactions was determined per person/months. The Cox proportional hazards regression model was used to identify predictors of major adverse drug responses. A p-value less than 0.05 with a 95% CI was used to declare statistical significance.

Result: The minimum and maximum follow-up time was 6 and 59 months, respectively. The study participants were followed for a total of 9916 person-months. The incidence rate of major adverse drug reactions was 3.5 /1000 person-months. Advanced clinical stages of HIV/AIDS (III and IV) [adjusted hazard ratio = 7.3, 95% CI: 2.74-19.60)], poor treatment adherence [adjusted hazard ratio = 0.33, 95% CI: 0.21-0.42], taking antiretroviral treatment twice and more [adjusted hazard ratio = 3.43, 955 CI: (1.26-9.33)] and not taking opportunistic infection prophylaxis [adjusted hazard ratio = 0.35, 95% CI: 0.23-0.52)] were predictors of major adverse drug reactions.

Conclusion: The incidence rate of major adverse drug reactions among children on antiretroviral treatment was congruent with studies in Ethiopia. Advanced clinical stages of HIV/AIDS, poor treatment adherence, taking antiretroviral treatment medications twice or more, and not taking opportunistic infection prophylaxis were predictors of major adverse drug reactions.

PubMed Disclaimer

Conflict of interest statement

The author(s) received no specific funding for this work.

Figures

Fig 1
Fig 1. Schematic diagram representation the sampling procedure of the study, northwest Amhara region public health hospital among children on ART, 2023.
Fig 2
Fig 2. Kaplan Meier curve estimate of overall survival status of children on ART drug at selected public hospital, northwest Amhara, Ethiopia, 2023.
(n = 380).
See this image and copyright information in PMC

References

    1. Mahy MI, Sabin KM, Feizzadeh A, Wanyeki I: Progress towards 2020 global HIV impact and treatment targets. Journal of the International AIDS Society 2021, 24:e25779. doi: 10.1002/jia2.25779 - DOI - PMC - PubMed
    1. Case KK, Johnson LF, Mahy M, Marsh K, Supervie V, Eaton JW: Summarizing the results and methods of the 2019 Joint United Nations Programme on HIV/AIDS HIV estimates. AIDS (London, England) 2019, 33(Suppl 3):S197. doi: 10.1097/QAD.0000000000002440 - DOI - PMC - PubMed
    1. Unicef: Children and AIDS: statistical update. New York: UNICEF; 2017.
    1. FMoHo E: National consolidated guidelines for comprehensive HIV prevention, care and treatment. Geneva: World Health Organization; 2020.
    1. Kopciuch D, Zaprutko T, Paczkowska A, Ratajczak P, Zielińska‐Tomczak Ł, Kus K, et al.: Safety of medicines—Pharmacists’ knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Pharmacoepidemiology and Drug Safety 2019, 28(12):1543–1551. doi: 10.1002/pds.4792 - DOI - PubMed